DECN - Decision Diagnostics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0280
0.0000 (0.00%)
As of 12:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0280
Open0.0276
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0276 - 0.0280
52 Week Range0.0100 - 0.1000
Volume44,000
Avg. Volume232,081
Market Cap2.148M
Beta (3Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE

    After Disclosing the Choice of Licensing Partner Last Week, DECN Receives Two New Accretive Propositions for Its Panacea GenUltimate! TBG

    LOS ANGELES, CA / ACCESSWIRE / August 8, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses that has been licensed to Fetch 4Pets, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN Chooses to License its Genultimate TBG Technology to Perfectly Situated Partner, Anticipates Agreement Will Yield Revenue Stream in Excess of $100 Million Over 5 Year Term, Company to Retain its Intellectual Property

    LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN's Appeal To Be Heard In Case Against J&J Over A Grossly Unfair Ruling And Lower Court's Termination Of The Case Against Their Court Wounded Adversary

    LOS ANGELES, CA / ACCESSWIRE / July 18, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! TBG Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN in Pact with Mega Pet Products Retailer Fetch for Pets Tripling Market For Company's Petsure Test Strips and Genultimate! 4pets Test Strips and Meters

    LOS ANGELES, CA / ACCESSWIRE / June 25, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered ...

  • ACCESSWIRE

    DECN Narrows Choices Of Likely Strategic Partners To Two, Serious Talks Begin

    LOS ANGELES, CA / ACCESSWIRE / June 19, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched on June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Discusses Current Financings with Aplha Capital Anstalt, Accepts Latest Proposition from Solicited Party, Will Choose from Two Proposals to Bring Closure

    LOS ANGELES, CA / ACCESSWIRE / June 13, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched on June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Discusses Propositions Received For Its GenUltimate TBG

    LOS ANGELES, CA / ACCESSWIRE / June 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched yesterday June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Accepts 4th Unsolicited Proposition for its GenUltimate TGB Product, and Today Launches its GenUltimate TGB Product into Select International Markets

    DECN Awaits Major Proposition On Or About June 10, Notifies Two Entities That Their Earlier Propositions Do Not Meet Requirements, Does Not Request Counter-Proposals LOS ANGELES, CA / ACCESSWIRE / June ...

  • ACCESSWIRE

    DECN to Launch Panacea GenUltimate TBG Diabetic Test Strip and Precise Meter June 6 in Select Off-Shore Markets, with Initial Plan To Target Users And Former Users Of The J&J/Lifescan Meters

    Almost 6 Million Users And Former Users Of The J&J/Lifescan Meters Can Choose Between Using Genultimate TBG Test Strips With Their Older Meters, Or Choose, In A Company Sponsored Merchandising Initiative, ...

  • ACCESSWIRE

    DECN Discusses Marketplace Intrique Surrounding Its Panacea Product Genultimate TBG, As It Readies June 6 Introduction

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ('Sunshine') diabetes test strip, the internationally launched GenSure! ('Feather') diabetes test strip, and its GenChoice! ('Ladybug') test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ('Dragonfly') highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    DECN to Discuss in Detail Three Major Events Just After Memorial Day Holiday

    Company Plans to Communicate 3rd Offer for the Monitizing Its New "TBG" Products, Developments in Big Box Efforts And the J&J Litigation LOS ANGELES, CA / ACCESSWIRE / May 23, 2019 / Decision ...

  • ACCESSWIRE

    DECN Sets Plan to Make Upcoming Patent Infringement Appeal Hearing and Mediation with Johnson & Johnson a Foundation for Substantial Recovery

    LOS ANGELES, CA / ACCESSWIRE / May 9, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ('Sunshine') diabetes test strip, the internationally launched GenSure! ('Feather') diabetes test strip, and its GenChoice! ('Ladybug') test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ('Dragonfly') highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    DECN's Appeal Nearing Oral Arguments in its Patent Battle with Johnson & Johnson Over the Unjust Ruling in the Nevada Lower Court

    LOS ANGELES, CA / ACCESSWIRE / May 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ("Dragonfly") highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    In Prelude to Probable Transaction DECN Decides to Infuse its Outre' Precise, TBG Technology to its GenChoice Test Strip, Now in FDA 510k Review

    LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce that its Korean R&D group in conjunction with CEO Keith Berman and his Stoney Fork new products experts have designed a method and determined meter specifics for the adding of the company's TBG technology to the upcoming GenChoice test strip now in FDA 510K review.

  • ACCESSWIRE

    DECN Expands Talks Involving Its GenUltimate TBG System, Balances Potential and Competing Outcomes with Recent Intro to 2nd Interested Party

    LOS ANGELES, CA / ACCESSWIRE / April 17, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce a series of recent events, ostensibly related to the company's announcement of the completion of advanced development for its GenUltimate TBG panacea product.

  • ACCESSWIRE

    DECN Hails Completion of Its Genultimate! TBG Panacea System, 3rd Party Testing to Begin in Next 7 Days, Clinical Trials Testing to Begin in May

    LOS ANGELES, CA / ACCESSWIRE / April 4, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce and communicate that the company's GenUltimate! TBG test strip and meter, the next generation panacea at-home testing product for diabetics, has completed its advanced development and begun testing for verification in advance of third party testing and patient clinical trials as a part of the company's application for 510K clearance through the U.S. FDA.

  • ACCESSWIRE

    DECN Launches Its Genultimate 4Pets and Avantage Meter, Ground-Breaking Products for the Testing of Dogs, Cats and Horses, Receives First Retail Orders, Establishes Innovative Rebate Program

    Launch Places DECN at the Top of Tier in the Fast Growing Pet Testing Market with Both Proprietary Products and Generics that Work on Market Leading Systems LOS ANGELES, CA / ACCESSWIRE / March 14, 2019 ...

  • ACCESSWIRE

    DECN in Pact with Alpha Capital Anstalt

    LOS ANGELES, CA / ACCESSWIRE / March 14, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan ...

  • ACCESSWIRE

    DECN Enters into Strategic Agreement with Paragon Sales and Marketing Inc. for Big Box Sales to Walmart, CVS, Walgreens, Costco and Cardinal Health

    Company Moves to Next Step, Builds Foundation for Increased Revenues, Branding And Positioning, as Well as a Handsome Settlement or M&A Transaction LOS ANGELES, CA / ACCESSWIRE / March 12, 2019 / Decision ...

  • ACCESSWIRE

    DECN Subsidiary Receives 510k Submission And ''K'' Numbers from FDA CDRH for Its Genchoice! Test Strip at the Close of the Government Shutdown

    LOS ANGELES, CA / ACCESSWIRE / January 30, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Today the company announces that they have received formal FDA CDRH notification that the GenChoice! test strip 510K application submission has been accepted and routed for review.

  • ACCESSWIRE

    DECN Discusses Its Panacea GenUltimate! TBG System, Offering Elite Performance And Premier Upgrade Path For 4+ Million Users Of Lifescan Ultra Meters

    LOS ANGELES, CA / ACCESSWIRE / January 17, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Today the company wishes to share expounded details regarding its new GenUltimate! panacea technology which will be used in the manufacture of its current GenUltimate! glucose test strip, its GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats and horses, and the GenUltimate! TBG test strip and Precise meter, the company's panacea product designed to achieve a new standard in at-home diabetes testing.

  • ACCESSWIRE

    DECN Subsidiaries Appeal Nevada District Court Trial Judge's Ruling to U.S. Court of Appeals for the Federal Circuit (The Patent Appeals Court)

    LOS ANGELES, CA / ACCESSWIRE / December 19, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 16 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Decision Diagnostics through its subsidiary corporations PharmaTech Solutions, Inc. and Decision IT Corp. announces today that the companies have appealed the court decision in its case against Johnson & Johnson (JNJ) and two Lifescan divisions, Nevada U.S. District Court case 2:2016cv00564, to the U.S. Court of Appeals for the Federal Circuit in Washington, DC.

  • ACCESSWIRE

    DECN Engages Second Korean Manufacturing Partner to Raise Its Factory Capacity by Two Million Boxes of ''GEN'' Test Strips Annually

    LOS ANGELES, CA / ACCESSWIRE / December 17, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 16 year olddiabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company’s current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses.

  • ACCESSWIRE

    DECN Releases its Strategic IP And Product Development Introduction Plan With a Summary of 2018 Achievements and 2019 Expectations

    LOS ANGELES, CA / ACCESSWIRE / December 11, 2018 / Decision Diagnostics Corp. (OTC:PINK: DECN) Decision Diagnostics Corp. is a 16 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of alternatives to legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce and communicate significant updates for several of our product lines including our GenChoice ("Ladybug"), GenPrecis! and GenPrecis! Precise Meter ("Dragonfly"), the PetSure! Test Strip ("small Ladybug"), the PetUltimate! Test Strip and PetUltimate! Avantage Meter ("Carnation").

  • ACCESSWIRE

    DECN Receives Completed Clinical Trials Report from its IRB and Anticipates Filing its U.S. FDA 510k Application for its Genchoice! Product on December 21, 2018

    DECN to Launch Genchoice! Product in Select International Markets January 2, 2019 and to File gor CE Mark in the EU and Health Canada Approval in Early 2019 LOS ANGELES, CA / ACCESSWIRE / December 4, 2018 ...